# Plasma tau and phosphorylated tau at T181 are altered in amyotrophic lateral sclerosis

Tiziana Petrozziello[1,2], Evan Mizerak[3], Aparna Krishnamoorthy[4], Rachel A. Donahue[5], Ayleen L. Castillo Torres[1], Ranee Zara B. Monsanto[1], Bruno L. Hammerschlag[5], Becky Fillingham[1], Pia Kivisäkk[5], Jamie Timmons[3], Kelly Fox[3], Steven E. Arnold[5], Joshua Cohen[3], Justin Klee[3], Sabrina Paganoni[1], Merit E. Cudkowicz[1], Lori B. Chibnik[5,6], James D. Berry[1], Ghazaleh Sadri-Vakili[1]

[1] Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, MA 02129, USA.
[2] Lurie Center for Autism, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02129, USA.
[3] Amylyx Pharmaceuticals Inc., Cambridge, MA 02141, USA.
[4] Biostatistics Center, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
[5] Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
[6] Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.

**Running title:** Plasma pTau is increased in ALS

***Corresponding author***: Ghazaleh Sadri-Vakili, Ph.D., MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg. 114 16th Street, R2200, Charlestown, MA 02129

Telephone: 617-724-1487

Fax: 617-724-1480

Email: gsadrivakili@mgh.harvard.edu

**Word count:** 2,996

**Abstract**

There is an unmet need for reliable biomarkers for amyotrophic lateral sclerosis (ALS). Recent studies have demonstrated that the levels of the microtubule-associated protein tau, are altered in plasma and cerebrospinal fluid (CSF) from people with ALS. Our previous findings demonstrated that while the ratio between tau and phosphorylated tau at T181 (pTau-T181) is decreased, increases in CSF tau correlated with faster disease progression in people with ALS. Here, we measured tau and pTau-T181 in plasma samples from participants with ALS and healthy controls (HC) using two methods (Quanterix Simoa and Meso Scale Discovery, MSD). Using both assays, there was an increase in pTau-T181 levels and in the pTau-T181:tau ratio in ALS compared to HC andlarger increases in pTau-T181 and pTau-T181:tau ratio at baseline correlated with faster ALS progression. Plasma total tau levels were increased in ALS compared to HC on the MSD assay and decreased on Quanterix Simoa assay. Collectively, our results suggest that plasma pTau-T181 levels are increased in ALS. Future studies should aim to clarify its role as a diagnostic or prognostic biomarker for ALS.

**Keywords:** tau, phosphorylated tau, amyotrophic lateral sclerosis, biomarker, disease progression

## Introduction

Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative disease characterized by a marked heterogeneity in both clinical manifestations and underlying pathogenic mechanisms (1-3). The ALS clinical presentation differs by age of onset, region of onset and progression rate and pattern (1). This variability complicates clinical diagnosis and ALS therapy development (4). Therefore, reliable diagnostic and/or prognostic biomarkers for ALS could hasten diagnosis, aid in clinical prognosticating and help improve ALS trial design.

Recent studies have begun to link alteration in the microtubule-associated protein tau (MAPT) to ALS (5-9). A growing body of evidence indicates that alterations in tau phosphorylation in CSF and plasma could serve as diagnostic and prognostic biomarkers for neurodegenerative tauopathies (10-11), which are marked by tau phosphorylation, accumulation and mutations (12-14). Recent studies have also shown that tau and pTau are altered in both CSF and plasma derived from people with ALS (5, 15-18). Our previous study demonstrated that CSF total tau levels were significantly increased in people with bulbar onset ALS and, more importantly, CSF total tau levels correlated with faster disease progression (5). Furthermore, our study was one of six reports that reliably recapitulated the finding that CSF pTau-T181:tau ratio is decreased in ALS participants (5, 15-18) and positively correlated with the score on the revised ALS functional rating scale (ALSFRS-R) (5). Recent findings have also reported an increase in plasma pTau-T181 in ALS (19-23), suggesting that alterations in total tau and pTau-T181 levels in ALS biofluids could potentially act as a disease monitoring, prognostic or diagnostic biomarker of ALS. Having said that, each of these biomarkers has different characteristics,

correlation with disease onset and progression and will be of benefit in contexts of use. Building on previously published findings, we sought to determine whether plasma total tau, pTau-T181 and pTau-T181:tau ratio are altered in ALS to help clarifying their potential biomarker uses. We investigated total tau and pTau-T181 levels and their ratio using two separate cohorts of samples and two methods, namely Quanterix Simoa and Meso Scale Discovery (MSD) assays.

## Materials and Methods

*Human plasma samples*. A random sampling of de-identified ALS and healthy control (HC) plasma samples and accompanying clinical information were obtained from the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Biofluid Repository at Mass General Hospital between 2008 and 2023 from participants in multi-site research studies. Blood was collected using K2EDTA tubes, and centrifuged at 1,750 g for 10 min. The supernatants were then collected, aliquoted into cryovials and frozen at -80°C within 2 h of collection. Sample were stored below -70°C, with no freeze-thaw cycles.

This study involved participants grouped in two cohorts, defined as ‘cohort 1’ and ‘cohort 2’.

Cohort 1 included longitudinally collected samples from HC (n = 52) and individuals with ALS (n = 76). HC group included 50% male individuals, while ALS group included 63% male individuals. Mean age at screening for HC was 48.4 years (SD = 16.1), while mean age for ALS individuals was 61.8 years (SD = 11.2). Thirteen participants with ALS (22%) had bulbar onset disease, while 40 individuals (68%) had limb onset ALS.

Cohort 2 included samples collected from HC (n = 90) and individuals with ALS (n = 98) only from a single time point. HC group from cohort 2 included 54% male individuals, while ALS group included 51% male individuals. Mean age at screening for HC was 45.7 years (SD = 7.8) while mean age for ALS individuals was 45.8 years (SD = 8.3). Ten individuals with ALS (13%) had bulbar onset disease, while 66 individuals (84%) had limb onset ALS.

Individuals with ALS from cohorts 1 and 2 had similar baseline characteristics, except that participants from cohort 2 were younger and had shorter disease duration (median disease duration = 14.0, (Q1, Q3) = (7.7, 22.8)) compared to individuals from cohort 1 (median disease duration = 35.51, (Q1, Q3) = (16.0, 47.0)). The average ALSFRS-R score was lower in cohort 1 (mean ALSFRS-R score = 35, SD = 7.9) in participants with ALS from cohort 1 compared to individuals with ALS from cohort 2 (mean ALSFRS-R score = 38.3, SD = 6.9). Demographics of participants with ALS and HC from both cohorts are reported in Table 1.

*Quanterix Simoa assay*. Plasma levels of pTau-T181 and total tau were measured using Simoa Assay kits (#104111, pTau-181 Advantage V2.1 kit; #101552, Tau Advantage Kit; Quanterix Corporation, Billerica, MA) on a fully automated Quanterix HD-X Analyzer at the Mass General Institute for Neurodegenerative Disease (MIND) Biomarker Core at Massachusetts General Hospital according to manufacturer's instructions and as previously reported (5, 24). Briefly, plasma samples were centrifuged at 3,000 g for 10 min, diluted 1:4 in Quanterix sample diluent, and measured in duplicate across two runs for total tau and three runs for pTau-T181. Three analytical controls spanning the range

of the analytes were included in all runs to account for run-to-run variability. The functional LLOQ was 8 pg/mL for pTau-T181 and 0.06 pg/mL for total tau. The coefficient of variance (CV) for duplicates was 6.4±6.2% (mean±SD) for pTau-T181 and 9.5%±8.1% for total tau. The standardized means of the analytical controls fell within the predefined acceptance limit of 80-120% of the mean for pTau-T181 but not for total tau (68-132%). No run-to-run normalization was consequently performed for pTau-T181, while total Tau was normalized using the analytical controls.

*Meso Scale Discovery assay*. Plasma tau and pTau-T181 were measured by using a ECLIA S-Plex Human Tau (total) kit (#K151APSS, Meso Scale Discovery), and a S-Plex Human Tau (pT181) kit (#K151AGMS, Meso Scale Discovery) according to manufacturer's instructions. Briefly, samples were centrifuged at 2,000 g for 3 min after thawing. Undiluted samples, calibrators and QCs were added to coated plates and incubated for 90 min at room temperature (RT). Next, the plates were incubated consecutively with the turbo-boost, enhancer and turbo-tag (detection) solutions. Lastly, MSD read buffer was added before analysis in an MSD reader.

*Statistics.* Normal distribution of measured data was not assumed regardless of sample size or characteristics. The data are presented as bar graphs demonstrating individual values with the whiskers representing the standard error or as noted individual value plots with the central line representing the median and the whiskers representing the interquartile range, as noted. For plasma analysis, the pre-baseline ALSFRS-R slope was calculated as the [(48 – baseline ALSFRS-R score)/(months between onset of ALS

weakness or spasticity and the baseline study visit)]. Summary slopes of ALSFRS-R total score and the plasma measures were estimated from the observed values using a mixed effects model with a fixed effect for time and a random intercept and slope for each participant with an unstructured covariance. Additionally, participant-level slopes in plasma measures and ALSFRS-R, measured as unit change per month, were compared using linear regression with ALSFRS-R slope as outcome and each plasma measure modeled separately. Adjustment for disease duration was considered as a confounder. Comparisons between groups were performed using a non-parametric Mann-Whitney *U* test. Correlations of plasma measures with clinical measures at the single time points were performed as non-parametric Spearman correlations. Comparisons with clinical measures were not corrected for multiple comparisons. All tests were two sided with a significance level of 0.05, and exact *p* values are reported. Analyses were performed using GraphPad Prism and R, a language and environment for statistical computing (https://www.R-project.org/).

*Study approval.* All human samples used in this study were de-identified. The collection, storage and sharing of these samples was approved by the Mass General Brigham Institutional Review Board (Boston, MA, USA).

## Results

### Total tau and pTau-T181 levels are altered in ALS plasma.

To determine whether tau phosphorylation could serve as biomarkers for ALS, we measured total tau, pTau-T181 and their ratio in two large and independent cohorts - both

from the NEALS biorepository, but with no overlapping participants. Each consisted of plasma samples derived from participants with ALS and HC. These cohorts are referred to as ‘cohort 1’ and ‘cohort 2’ respectively. Baseline characteristics for both cohort are presented in Table 1.

First, total tau, pTau-T181, and pTau-T181:tau ratio were assessed in cohort 1 by Quanterix Simoa assay. Total tau levels in ALS plasma were significantly lower than in HC (0.88 (SD = 0.53) vs 1.49 (SD = 0.61), $p < 0.0001$) (Figure 1A). pTau-T181 levels in ALS plasma were significantly higher than HC (30.29 (SD = 28.5) vs 12.97 (SD = 10.41), $p = 0.0004$) (Figure 1B). Similarly, pTau-T181:tau ratio was significantly higher in ALS plasma than HC (52.07 (SD = 61.25) vs 13.18 (SD = 15.40), $p < 0.0001$) (Figure 1C).

Next, we assessed total tau, pTau-T181 levels and their ratio in cohort 2 by MSD assay. Total tau levels in ALS plasma were significantly higher than in HC (40.07 (SD = 34.84) vs 25.85 (SD = 13.76), $p = 0.0003$) (Figure 1D). pTau-T181 levels in ALS plasma were significantly higher than HC (6.77 (SD = 6.27) vs 2.18 (SD = 0.94), $p < 0.0001$) (Figure 1E). Similarly, pTau-T181:tau ratio was significantly higher in ALS plasma than HC (0.37 (SD = 1.45) vs 0.098 (SD = 0.045), $p < 0.0001$) (Figure 1F).

**Alterations in plasma tau, pTau-T181 and pTau-T181:tau ratio were independent of region of onset.**

To determine whether measuring tau and pTau-T181 levels could help stratify people with ALS based on region of disease onset, we correlated the levels with bulbar vs limb onset. In cohort 1, total tau levels were decreased in both bulbar- (0.82 (SD = 0.48), $p = 0.0001$) (Figure 2A) and limb-onset ALS (0.80 (SD = 0.57), $p < 0.0001$) (Figure 2D) compared to

HC. pTau-T181 levels were increased in bulbar-onset (29.07 (SD = 19.21), p = 0.0016) (Figure 2B) and limb-onset ALS (28.81 (SD = 29.56), p = 0.0066) (Figure 2E) compared to HC. pTau-T181:tau ratio was increased in bulbar- (48.60 (SD = 39.49), p = 0.0001) (Figure 2C) and limb-onset ALS (50.07 (SD = 64.10), p = 0.0004) (Figure 2F) compared to HC.

In cohort 2, total tau levels were increased in both bulbar- (51.24 (SD = 40.59), p = 0.0083) (Figure 3A) and limb-onset ALS (39.50 (SD = 36.26), p = 0.0051) (Figure 3D) compared to HC. pTau-T181 levels were increased in bulbar-onset (8.13 (SD = 5.96), p = 0.0005) (Figure 3B) and limb-onset ALS (6.45 (SD = 5.12), p < 0.0001) (Figure 3E) compared to HC. pTau-T181:tau ratio was not different in bulbar-onset ALS (0.18 (SD = 0.12), p = 0.600) (Figure 3C), while it was higher in limb-onset ALS (0.43 (SD = 1.73), p < 0.0001) (Figure 3F) compared to HC.

**Plasma pTau-T181 levels correlated with faster ALS progression.**

Next, we correlated tau and pTau levels with clinical characteristics, including age, disease duration, and ALSFRS-R at the time of sample collection.

Our results demonstrated no statistically significant correlations; however, there was a negative correlation between age and total tau (R = -0.027, p = 0.84), and positive correlations between pTau-T181 (R = 0.073, p = 0.58), and pTau-T181:tau ratio (R = 0.067, p = 0.62) at the time of sample collection in cohort 1 (Figure 4A-C). Additionally, negative correlations between age and total tau (R = -0.084, p = 0.42), pTau-T181 (R = -0.084, p = 0.42), and pTau-T181:tau ratio (R = -0.08, p = 0.42) at the time of sample collection was reported in cohort 2 (Figure 4D-F).

There was a negative correlation between disease duration and total tau (R = -0.16, p = 0.22), and positive correlations between pTau-T181 (R = 0.19, p = 0.15), or pTau-T181:tau ratio (R = 0.2, p = 0.12) in cohort 1 (Figure 5A-C). There were positive correlations seen between disease duration and total tau (R = 0.02, p = 0.86), pTau-T181 (R = 0.062, p = 0.57), or pTau-T181:tau ratio (R = 0.033, p = 0.76) in cohort 2 (Figure 5D-F).

In cohort 1, ALSFRS-R at baseline had a negative correlation with total tau (R = -0.0014, p = 0.99), pTau-T181 (R = -0.086, p = 0.56) and pTau-T181:tau ratio (R = -0.086, p = 0.56) at the time of sample collection (Figure 6A-C); similarly, pre-baseline ALSFRS-R slope had a negative correlation with total tau (R = -0.064, p = 0.67), pTau-T181 (R = -0.061, p = 0.68) and pTau-T181:tau ratio (R = -0.0055, p = 0.97) at the time of sample collection (Figure 7A-C). In cohort 2, ALSFRS-R at baseline had negative correlation with total tau (R = -0.015, p = 0.89) and pTau-T181 (R = -0.014, p = 0.9) and positive correlations with pTau-T181:tau ratio (R = 0.023, p = 0.84) at the time of sample collection (Figure 6D-E); similarly, pre-baseline ALSFRS-R slope had negative correlation with total tau (R = -0.12, p = 0.31) and pTau-T181 (R = -0.096, p = 0.41) and positive correlation with pTau-T181:tau ratio (R = 0.044, p = 0.71) at the time of sample collection (Figure 7D-E).

Longitudinal analysis of ALS plasma from cohort 1 demonstrated a variability in the trajectories of tau, pTau-T181, and pTau-T181:tau ratio levels (Table 2). As expected, ALSFRS-R scores declined at an average rate of 0.48 (SD = 0.05) points per month ($p < 0.001$). Total tau revealed a statistically significant increase of 0.02 pg/mL (SD = 0.01) per month (p = 0.007), whereas pTau-T181 showed an average of 0.15 pg/mL (SD =

0.14) per month increase (p = 0.27) and pTau-T181:tau ratio showed an average of 0.10 pg/mL (SD = 0.36) decrease per month (p = 0.79) although not statistically significant (Table 2). Importantly, increases in pTau-T181 levels correlated with faster decline in ALSFRS-R over time, with a 1 pg/mL higher pTau-T181 level associated with a 0.20 points per month faster slope in ALSFRS-R decline (beta (SE) = 0.20 (0.07), 95%CI (0.06, 0.34), p = 0.007). Whereas total tau demonstrated a positive, yet non-significant association with ALSFRS-R decline (Beta (SE) = 1.18(1.69), 95%CI (-2.22, 4.59), p = 0.487), pTau-T181:tau ratio revealed no association (Beta(SE) = 0.00 (0.02), 95%CI (-0.03, 0.03), p = 0.960).

## Discussion

In this study, we confirmed previous findings demonstrating a significantly higher plasma pTau-T181 (19-23) and pTau-T181:tau ratio in ALS using two different cohorts of plasma samples as well as two methods of detection. Both assays also revealed that alterations in pTau-T181 and the ratio occurred with both bulbar and limb-onset ALS. These higher levels did not correlate with age at the time of sample collection. Elevated plasma pTau-T181 levels and pTau-T181:tau ratio correlated with faster slope of decline of the ALSFRS-R, supporting previous findings revealing increases in pTau-T181 over time in people with ALS with faster progressing disease (20). A previous study demonstrated that elevation in pTau-T181 in ALS plasma inversely correlated with ALSFRS-R (23), similar as what was seen in our cohorts.

Previous studies have suggested that elevations in CSF total tau correlated with faster ALS progression (5, 15-18). However, little has been known about total tau levels in ALS

plasma. To our knowledge, only a single study demonstrated a decrease in serum total tau levels in ALS (25). Somewhat surprisingly, our results demonstrated a decrease in total tau in plasma samples from cohort 1 (Quanterix Simoa assay), but an increase in cohort 2 (MSD assay). This disagreement could be due to a different behavior of plasma tau in these cohorts, perhaps from cofounders such as concomitant medications, coexisting frontotemporal dementia, or other unknown differences between the cohorts. Alternatively, it is possible that assay performance was different. Although both techniques are highly sensitive, the antibodies likely bind to different tau epitopes, resulting in that the species of tau recognized by the two assays may be different, explaining the opposite results. However, additional studies are required to validate this hypothesis.

The lower levels of total tau in ALS compared to HC in cohort 1 was surprising, given that tau levels increase with age (26-27) and that the samples in cohort 1 consisted of older individuals with a shorter disease course at time of clinic visit when the samples were collected (Table 1). Future studies will include larger cohorts of samples and test using both platforms on the same samples.

Plasma total tau levels from cohort 1 revealed a statistically significant increase in tau levels over time ($p = 0.007$; Table 2). Cohort 2 consisted only of single timepoint samples, and replication of these longitudinal results is important.

Our findings replicate recently published results demonstrating a significant increase in plasma pTau-T181 levels in ALS (19-23). Additionally, we also reported a significant increase in pTau-T181:tau ratio in ALS plasma. Increases in both pTau-T181 levels and pTau-T181:tau ratio were consistent across two different cohorts and two testing

methodologies. Furthermore, the correlation of pTau-T181 and pTau-T181:tau ratio with faster disease progression in this study support previous findings (20) and suggests that they may be useful as prognostic biomarkers for ALS. It is now clear that CSF pTau-T181 and pTau-T181:tau ratio are decreased in ALS (5; 15-18) and do not correlate with the increase in plasma as shown in this study and previously (19-22). This discrepancy in CSF vs plasma pTau-T181 levels has a number of plausible explanations. The originating source for plasma may be peripheral tissue as was reported recently (22) or it may be bound to proteins in the plasma but not the CSF (matrix effect), or it may be cleared or metabolized quickly in the plasma but not in CSF. Determining which factors are at play will take future studies. Given that pTau-T181 is a validated biomarker for AD (10, 28), it will be helpful to compare protein levels between ALS and AD to determine whether the alterations are relevant and able to distinguish between diseases and this is a future direction for our studies.

Taken together, our results in two large and independent cohorts of plasma support previous findings and confirm that plasma pTau-T181 and pTau-T181:tau ratio levels are significantly increased in ALS. Furthermore, increases in plasma pTau-T181 correlated with faster disease progression, suggesting that pTau-T181 may serve as a potential biomarker for ALS, though more work must be done to clarify its kinetics and testing properties in the CSF as well as in plasma.

**Acknowledgments.** The authors would like to thank patients and their families for sample donation.

**Author contributions.** T.P. contributed to the study design, data collection, data analysis, and drafting of the manuscript. E.M., A.K., A.L.C.T., R.Z.B.M., B.L.H.M B.F., P.K., J.T., K.F. contributed to the data collection, data analysis, and editing of the manuscript. S.E.A., J.C., J.K., S.P., M.E.C., L.C., J.D.B. contributed to the study design and editing of the manuscript. GSV contributed to the study design, data analysis, drafting of the manuscript.

**Funding.** T.P. was supported by an award from The Linda and Mike Mussallem Foundation to Massachusetts General Hospital. G.S.V. was supported by the Andre Family. The MIND Biomarker Core was supported by NIA grant P30AG062421.

**Disclosure statement.**

SEA reports receiving institutional grant or sponsored research support from the Alzheimer's Association, Alzheimer Drug Discovery Foundation, Challenger Foundation, John Sperling Foundation, National Institutes of Health, Prion Alliance, AbbVie, Amylyx, Athira Pharma, Eli Lilly, Ionis Pharmaceuticals, Janssen Pharmaceutical/Johnson& Johnson, MarvelBiome, Novartis AG, Seer Bioscience, and SuperFluid; and payments for consulting and/or participation on scientific advisory boards of Allyx Therapeutics, BioVie Pharma, Bob's Last Marathon, Cassava Sciences, Cortexyme/Quince Therapeutics, EIP Pharma/CervoMed, Foster & Eldredge, Jocasta Neuroscience, Merck, Sage Therapeutics, and Vandria. EM, JT, KF, JC, and JK are full-time employees of and may have stock option ownership in Amylyx Pharmaceuticals, Inc.

**Data availability statement.** The data supporting the findings of this study are available within the article and/or its supplementary material.

**Table 1: Baseline characteristics for ALS cohorts 1 and 2**

| | Cohort 1 | | Cohort 2 | |
|---|---|---|---|---|
| | **HC (n = 52)** | **ALS (n = 76)** | **HC (n = 90)** | **ALS (n = 98)** |
| Age at sample collection, mean (SD), n | 48.4 (16.1), n=36 | 61.8 (11.2), n=59 | 45.65 (7.77), n=76 | 45.78 (8.30), n=96 |
| Sex, n male (%), n | 18 (50%), n=36 | 37 (63%), n=59 | 41 (54%), n=76 | 49 (51%), n=96 |
| pTau-T181, median [Q1, Q3], n | 14.36 [2.24, 20.70], n=41 | 24.73 [6.86, 43.94], n=76 | 2.01 [1.56, 2.54], n=85 | 5.19 [2.86, 8.41], n=96 |
| Total Tau, median [Q1, Q3], n | 1.40 [0.97, 2.00], n=48 | 0.72 [0.54, 1.03], n=76 | 22.23 [17.98, 29.61], n=90 | 27.92 [21.12, 42.92], n=98 |
| pTau-T181:total tau Ratio, median [Q1, Q3], n | 8.67 [1.25, 21.72], n=36 | 28.64 [6.63, 71.76], n=76 | 0.09 [0.07, 0.13], n=85 | 0.15 [0.09, 0.24], n=96 |
| **ALS disease characteristics** | | | | |
| Age at symptom onset, mean (SD), n | | 58.9 (11.5), n=59 | | 43.5 (8.9), n=96 |
| Site of Onset, Bulbar, n (%) | | 13 (22%), n=59 | | 10 (13%), n=79 |
| Site of Onset, Limb, n (%) | | 40 (68%), n=59 | | 66 (84%), n=79 |
| Disease Duration, Median [Q1, Q3], n | | 25.0 [16.0, 47.0], n=59 | | 14.0 [7.7, 22.8], n=89 |
| ALSFRS-R, mean (SD), n | | 35.0 (7.9), n=47 | | 38.3 (6.9), n=81 |
| Pre-baseline ALSFRS, mean (SD), n | | 0.58 (0.80), n=47 | | 1.42 (2.16), n=77 |

***Table 2. Trajectories of ALSFRS-R, total tau, pTau-T181, and pTau-T181: tau ratio in ALS plasma from cohort 1.***

| | **Slope** | **Slope SE** | **p-value** |
|---|---|---|---|
| ALSFRS-R | -0.48 | 0.05 | < 0.001 |
| tau | 0.02 | 0.01 | 0.007 |
| pTau-T181 | 0.15 | 0.14 | 0.273 |
| pTau-T181:tau ratio | -0.1 | 0.36 | 0.787 |

* Slope is measured as change per month, p-value tests if slope is different from 0

**References**

1. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918-29.

2. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162-72.

3. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.

4. Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5-6):453-6.

5. Petrozziello T, Amaral AC, Dujardin S, Farhan SMK, Chan J, Trombetta BA, et al. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Brain Pathol. 2022;32(2):e13035.

6. Petrozziello T, Bordt EA, Mills AN, Kim SE, Sapp E, Devlin BA, et al. Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2022;59(1):683-702.

7. Stevens CH, Guthrie NJ, van Roijen M, Halliday GM, Ooi L. Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. J Neuropathol Exp Neurol. 2019;78(7):605-14.

8. Ayaki T, Ito H, Komure O, Kamada M, Nakamura M, Wate R, et al. Multiple Proteinopathies in Familial ALS Cases With Optineurin Mutations. J Neuropathol Exp Neurol. 2018;77(2):128-38.

9. Moszczynski AJ, Strong W, Xu K, McKee A, Brown A, Strong MJ. Pathologic Thr(175) tau phosphorylation in CTE and CTE with ALS. Neurology. 2018;90(5):e380-e7.

10. Shoji M. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy. Adv Exp Med Biol. 2019;1184:393-405.

11. Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, et al. Tau as a biomarker of neurodegenerative diseases. Biomark Med. 2008;2(4):363-84.

12. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609-22.

13. Wolfe MS. The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo). 2012;2012:796024.

14. Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener. 2009;4:13.

15. Schreiber S, Spotorno N, Schreiber F, Acosta-Cabronero J, Kaufmann J, Machts J, et al. Significance of CSF NfL and tau in ALS. J Neurol. 2018;265(11):2633-45.

16. Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, Zaganas I, et al. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dement Geriatr Cogn Disord. 2017;44(3-4):144-52.

17. Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36(2):1072-4.

18. Grossman M, Elman L, McCluskey L, McMillan CT, Boller A, Powers J, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):442-8.

19. Cousins KAQ, Shaw LM, Shellikeri S, Dratch L, Rosario L, Elman LB, et al. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis. Ann Neurol. 2022;92(5):807-18.

20. Vacchiano V, Mastrangelo A, Zenesini C, Baiardi S, Avoni P, Polischi B, et al. Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2023;94(6):428-35.

21. Verde F, Milone I, Colombo E, Maranzano A, Dubini A, Colombrita C, et al. Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis. Neurol Sci. 2023;44(10):3697-702.

22. Abu-Rumeileh S, Scholle L, Mensch A, Grosskopf H, Ratti A, Kolsch A, et al. Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis. Nat Commun. 2025;16(1):2019.

23. Thomas EV, Han C, Kim WJ, Asress S, Li Y, Taylor JA, et al. ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression. Ann Clin Transl Neurol. 2025.

24. Petrozziello T, Huntress SS, Castillo-Torres AL, Quinn JP, Connors TR, Auger CA, et al. Age-Dependent Increase in Tau Phosphorylation at Serine 396 in Huntington's Disease Prefrontal Cortex. J Huntingtons Dis. 2023;12(3):267-81.

25. Falzone YM, Domi T, Mandelli A, Pozzi L, Schito P, Russo T, et al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(7):1930-9.

26. Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Alterations in tau protein metabolism during normal aging. Dementia. 1996;7(2):95-103.

27. Chatterjee S, Sealey M, Ruiz E, Pegasiou CM, Brookes K, Green S, et al. Age-related changes in tau and autophagy in human brain in the absence of neurodegeneration. PLoS One. 2023;18(1):e0262792.

28. Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med. 2020;12(12):e12921.

## Figures




**Figure 1. Total tau, pTau-T181 and pTau-T181:tau ratio levels are altered in ALS plasma.** While there was a significant decrease in (**A**) tau levels (Mann-Whitney U test = 737.5; $p < 0.0001$), (**B**) pTau-T181 levels (Mann-Whitney U test = 918.5; $p = 0.0004$), and (**C**) pTau-T181:tau ratio (Mann-Whitney U test = 701; $p < 0.0001$) were significantly increased in ALS plasma (n = 76) compared to HC (n = 52) in cohort 1, as measured by Quanterix Simoa Assay. Additionally, there was a significant increase in (**D**) tau levels (Mann-Whitney U test = 3253; $p = 0.0003$), (**E**) pTau-T181 levels (Mann-Whitney U test = 1359; $p < 0.0001$), and (**F**) pTau-T181:tau ratio (Mann-Whitney U test = 2092; $p < 0.0001$) in ALS plasma (n = 98) compared to HC (n = 90) in cohort 2, as measured by MSD assay. *** $p < 0.001$; **** $p < 0.0001$.




**Figure 2. Alterations in tau and pTau-T181 are independent of region of onset in cohort 1.** (**A**) Tau levels were significantly decreased (Mann-Whitney U test = 131; p = 0.0001), while (**B**) pTau-T181 levels (Mann-Whitney U test = 124; p = 0.0016), and (**C**) pTau-T181: tau ratio (Mann-Whitney U test = 94; p = 0.0001) were significantly increased in bulbar-onset ALS (n = 13) compared to HC (n = 52). Similarly, while (**D**) tau levels were significantly decreased (Mann-Whitney U test = 525.5; p < 0.0001), there was a significant increase in (**E**) pTau-T181 levels (Mann-Whitney U test = 712; p = 0.0066), and (**F**) pTau-T181:tau ratio (Mann-Whitney U test = 526; p = 0.0004) in limb-onset ALS (n = 40) compared to HC (n = 52). ** p < 0.01; *** p < 0.001; **** p < 0.0001.




**Figure 3. Alterations in tau and pTau-T181 are independent of region of onset in cohort 2.** While (**A**) tau levels (Mann-Whitney U test = 235; p = 0.0083), and (**B**) pTau-T181 levels (Mann-Whitney U test = 158; p = 0.0005) were significantly increased, (**C**) pTau-T181: tau ratio (Mann-Whitney U test = 283; p = 0.0600) was not changed in bulbar-onset ALS (n = 10) compared to HC (n = 94). Similarly, (**D**) tau levels (Mann-Whitney U test = 2336; p = 0.0051), (**E**) pTau-T181 levels (Mann-Whitney U test = 880; p < 0.0001), and (**F**) pTau-T181:tau ratio (Mann-Whitney U test = 1324; p < 0.0001) were significantly increased in limb-onset ALS (n = 66) compared to HC (n = 94). ** p < 0.01; *** p < 0.001; **** p < 0.0001.




**Figure 4. Plasma tau, pTau-T181 and their ratio did not correlate with age at the time sample collection.** (**A**) Tau levels (Spearman correlation, R = -0.027; p = 0.84), (**B**) pTau-T181 levels (Spearman correlation, R = 0.073; p = 0.58), and (**C**) pTau-T181:tau ratio (Spearman correlation, R = 0.067; p = 0.62) did not correlate with age at the time of sample collection in cohort 1. Similarly, (**D**) tau levels (Spearman correlation, R = 0.029; p = 0.78), (**E**) pTau-T181 levels (Spearman correlation, R = -0.084; p = 0.42), and (**F**) pTau-T181:tau ratio (Spearman correlation, R = -0.084; p = 0.42) did not correlate with age at the time of sample collection in cohort 2.




**Figure 5. Plasma tau, pTau-T181, and their ratio did not correlate with disease duration.** (**A**) Tau levels (Spearman correlation, R = -0.16; p = 0.22), (**B**) pTau-T181 levels (Spearman correlation, R = 0.19; p = 0.15), and (**C**) pTau-T181:tau ratio (Spearman correlation, R = 0.2; p = 0.12) did not correlate with ALS duration in cohort 1. Similarly, (**D**) tau levels (Spearman correlation, R = 0.02; p = 0.86), (**E**) pTau-T181 levels (Spearman correlation, R = 0.062; p = 0.57), and (**F**) pTau-T181:tau ratio (Spearman correlation, R = 0.033; p = 0.76) did not correlate with ALS duration in cohort 2.




**Figure 6. Plasma tau, pTau-T181, and their ratio did not correlate with baseline ALSFRS-R score.** (**A**) Tau levels (Spearman correlation, R = -0.0014; p = 0.99), (**B**) pTau-T181 levels (Spearman correlation, R = -0.086; p = 0.56), and (**C**) pTau-T181:tau ratio (Spearman correlation, R = -0.086; p = 0.56) did not correlate with the total ALSFRS-R score in cohort 1. Similarly, (**D**) tau levels (Spearman correlation, R = -0.015; p = 0.89), (**E**) pTau-T181 levels (Spearman correlation, R = -0.014; p = 0.9), and (**F**) pTau-T181:tau ratio (Spearman correlation, R = 0.023; p = 0.84) did not correlate with the total ALSFRS-R score in cohort 2.




**Figure 7. Plasma tau, pTau-T181 levels, and their ratio did not correlate with pre-baseline ALSFRS-R slope.** (**A**) Tau levels (Spearman correlation, R = -0.064; p = 0.67), (**B**) pTau-T181 levels (Spearman correlation, R = -0.061; p = 0.68), and (**C**) pTau-T181:tau ratio (Spearman correlation, R = -0.0055; p = 0.97) did not correlate with the pre-baseline ALSFRS-R slope in cohort 1. Similarly, (**D**) tau levels (Spearman correlation, R = -0.12; p = 0.31), (**E**) pTau-T181 levels (Spearman correlation, R = -0.096; p = 0.41), and (**F**) pTau-T181:tau ratio (Spearman correlation, R = 0.044; p = 0.71) did not correlate with the pre-baseline ALSFRS-R slope in cohort 2.